HOME >> MEDICINE >> NEWS
Major new study finds long-acting calcium channel blockers inferior to other antihypertensive drugs

Up to 85,000 unnecessary heart attacks and cases of heart failure may occur worldwide every year among the estimated 28 million users of longer-acting calcium channel blockers (CCBs), a class of drugs used to treat high blood pressure, according to the results of a study reported today at the European Society of Cardiology meeting in Amsterdam.

The combined analysis of nine randomized clinical trials, with a total of more than 27,000 patients, showed that the longer-acting CCBs are inferior to other proven and less expensive drugs in preventing the cardiovascular complications of hypertension.

The study was conducted at Wake Forest University School of Medicine in Winston-Salem, the University of Washington-Seattle, and Albert Einstein College of Medicine, Bronx, New York.

"The results are remarkably consistent across the trials," said Marco Pahor, M.D., professor of internal medicine at Wake Forest and the study's lead researcher. "In the CCB-treated patients, the risk of a heart attack was 27 percent higher, the risk of heart failure was 26 percent higher and the risk of any major cardiovascular event was 11 percent higher. There was no difference in stroke or total mortality; and there was no evidence of differences among the CCBs tested."

The results add to a growing body of evidence that antihypertensive drugs, despite having equal effect on blood pressure, may vary in their ability to prevent heart attacks and congestive heart failure, said Curt D. Furberg, M.D., Ph.D., professor of public health sciences at Wake Forest University School of Medicine and a co-researcher of the study.

"The overuse of these less effective CCBs -- which can cost 10 to 15 times more than diuretics -- is a major avoidable clinical problem that requires immediate attention," Furberg told the cardiology society meeting in Amsterdam. The study examined the results of nine long-term trials involving 27,743 patients, with a total of about 120,000 person-years
'"/>

Contact: Karen Richardson
krchrdsn@wfubmc.edu
336-716-4587
Wake Forest University Baptist Medical Center
28-Aug-2000


Page: 1 2 3

Related medicine news :

1. Major review of subway systems suggests potential for significant health and safety hazards
2. Major step forwards for vaccine against cervical cancer
3. Majority of cigarettes in the US smoked by nicotine-dependent or psychiatrically ill persons
4. Major overhaul needed in end-of life care for patients with dementia
5. Major overhaul needed in end-of life care for patients with dementia
6. Major radiology journal offers unrestricted access to recently archived articles
7. Major study: Bioartificial liver reduces mortality by 44 percent in acute liver-failure patients
8. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
9. Major agreement reached at heart health conference
10. Major risk factors identified for sudden infant death syndrome
11. Major cause of painful gastroenteritis under study at MCG

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
Breaking Medicine Technology:
Cached News: